论文部分内容阅读
目的研究喘可治注射液对儿童哮喘的临床疗效和安全性。方法 6 8例 5～ 14岁哮喘或哮喘合并过敏性鼻炎患儿 ,随机分为治疗组和对照组 ,治疗组采用喘可治治疗 ,对照组采用银杏注射液治疗 ,观察两组每日症状评分 ,早、晚最大呼气峰流速测定 (PEF) ,肺功能检查 (FEV1)。结果治疗后症状评分中位数治疗组为 6 0 (M 2 5～M 75 :4 9～ 2 1 5 ) ,对照组为 10 0 (M 2 5～M 75 :6 2～ 2 7 5 ) ,两组比较差异有显著性 ;PEF变异率治疗组为 (4 3± 5 1) % ,对照组为 (5 9± 6 7) % ,两组比较差异有显著性 ;FEV1%较对照组显著改善。结论临床研究发现喘可治有助于改善哮喘患儿临床症状 ,降低PEF变异率 ,改善肺功能 ,有利于哮喘症状的改善和长期稳定
Objective To study the clinical efficacy and safety of Chuankezhi Injection in children with asthma. Methods Sixty-eight children aged 5-14 years with asthma or asthma with allergic rhinitis were randomly divided into treatment group and control group. The treatment group was treated with Chuankezhi, while the control group was treated with Ginkgo biloba injection. The daily symptom score , Morning and evening peak expiratory flow rate (PEF), pulmonary function test (FEV1). Results After treatment, the median symptom scores were 60 (M 2 5 ~ M 75: 49 ~ 2 1 5) in the treatment group and 10 0 (M 2 5 ~ M 75: 6 2 ~ 25 7) in the control group, The difference between the two groups was significant; PEF mutation rate was (43 +/- 51)% in the treatment group and (59 +/- 67)% in the control group, with significant difference between the two groups; FEV1% was significantly improved compared with the control group . Conclusions The clinical study found that Chuankezhi can help to improve the clinical symptoms of children with asthma, reduce the mutation rate of PEF and improve lung function, which is beneficial to the improvement of asthma symptoms and long-term stability